Alexion Pharmaceuticals said Wednesday it is buying Sweden’s Wilson Therapeutics for $855 million to expand its pipeline of drugs to treat rare diseases, as the pace of deal-making in the biotech sector ticks higher.

The centerpiece of the Alexion transaction is Wilson’s lead drug WTX101, an oral agent in Phase 3 development as a treatment for Wilson disease, a rare, inherited disorder that causes liver and neurologic problems. WTX101 works by binding to copper in the bloodstream and promoting its removal in the liver.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy